# ESP Study: A Study to Assess the Effect of Adding Fuzeon (Enfuvirtide) to an Antiretroviral Regimen in Fuzeon-Naive Patients With Sustained HIV Viral Suppression.

> **NCT00461266** · PHASE4 · WITHDRAWN · sponsor: **Hoffmann-La Roche**

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** enfuvirtide [Fuzeon]
- **DRUG:** Antiretroviral therapy

## Key facts

- **NCT ID:** NCT00461266
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2007-04
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Slow recruitment
- **Last updated:** 2016-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00461266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00461266, "ESP Study: A Study to Assess the Effect of Adding Fuzeon (Enfuvirtide) to an Antiretroviral Regimen in Fuzeon-Naive Patients With Sustained HIV Viral Suppression.". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT00461266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*